Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness

Area of Science:

• Microbiology
• Vaccinology
• Immunology

Background:

• For 40 years, vaccines against Neisseria meningitidis serogroup B (MenB) have been developed, with some success in targeting epidemic strains.
• Current vaccines include monovalent outer membrane vesicle (OMV) vaccines and newer formulations like 4CMenB and factor H binding protein (rLP2086) based vaccines.
• The actual protective efficacy of these MenB vaccines against currently circulating strains is not well understood.

Purpose of the Study:

• To evaluate the true protective coverage of existing MenB vaccines against major circulating MenB clonal lineages.
• To identify specific vaccine antigens associated with protection against MenB disease.
• To guide future vaccine development strategies.

Main Methods:

• Conducting Phase IV post-implementation evaluations.
• Measuring vaccine effectiveness against specific MenB clonal lineages.
• Utilizing whole-genome sequencing and bioinformatics for antigen analysis.

Main Results:

• The protective coverage of current MenB vaccines against circulating isolates remains largely unknown.
• Further research is required to link specific antigens to protective immunity.
• Genomic and bioinformatics approaches show promise for future vaccine design.

Conclusions:

• There is a critical need for Phase IV studies to assess MenB vaccine effectiveness.
• Identifying protective antigens is crucial for improving MenB vaccine design.
• Future MenB vaccines may be composed of antigen mosaics based on key outer membrane proteins like PorA and FetA.